210 related articles for article (PubMed ID: 33804754)
1. Lipids and Antiplatelet Therapy: Important Considerations and Future Perspectives.
Đukanović N; Obradović S; Zdravković M; Đurašević S; Stojković M; Tosti T; Jasnić N; Đorđević J; Todorović Z
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804754
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of clopidogrel.
Sarafoff N; Byrne RA; Sibbing D
Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
[TBL] [Abstract][Full Text] [Related]
3. Regulators of platelet cAMP levels: clinical and therapeutic implications.
Noé L; Peeters K; Izzi B; Van Geet C; Freson K
Curr Med Chem; 2010; 17(26):2897-905. PubMed ID: 20858171
[TBL] [Abstract][Full Text] [Related]
4. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
5. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance.
Dorsam RT; Murugappan S; Ding Z; Kunapuli SP
Hematology; 2003 Dec; 8(6):359-65. PubMed ID: 14668029
[No Abstract] [Full Text] [Related]
7. Oral Antiplatelet Therapy in Coronary Disease.
Falcão Gonçalves P; Menezes Falcão L
Am J Ther; 2017; 24(6):e744-e750. PubMed ID: 26752652
[TBL] [Abstract][Full Text] [Related]
8. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493
[TBL] [Abstract][Full Text] [Related]
9. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
[TBL] [Abstract][Full Text] [Related]
10. Sepsis favors high-on-clopidogrel platelet reactivity.
Akinosoglou K; Perperis A; Theodoraki S; Alexopoulos D; Gogos C
Platelets; 2018 Jan; 29(1):76-78. PubMed ID: 28635374
[TBL] [Abstract][Full Text] [Related]
11. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
[TBL] [Abstract][Full Text] [Related]
12. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
13. Laboratory Monitoring of Platelet P2Y12 Receptor Inhibitors and Reversal of Antiplatelet Agents.
Senzel L; Ahmed T; Spitzer ED
Am J Clin Pathol; 2019 Jun; 152(1):1-6. PubMed ID: 30395148
[TBL] [Abstract][Full Text] [Related]
14. P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.
So DYF; Bagai A; Tran U; Verma S; Mehta SR
Curr Opin Cardiol; 2017 Sep; 32(5):617-626. PubMed ID: 28661903
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
[TBL] [Abstract][Full Text] [Related]
16. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
17. The effect of smoking on residual platelet reactivity to clopidogrel: a systematic review and meta-analysis.
Liu Z; Xiang Q; Mu G; Xie Q; Zhou S; Wang Z; Chen S; Hu K; Gong Y; Jiang J; Cui Y
Platelets; 2020; 31(1):3-14. PubMed ID: 30744477
[TBL] [Abstract][Full Text] [Related]
18. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
[TBL] [Abstract][Full Text] [Related]
19. A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y
Li X; Liu P; Xu Z; Sun D; Gu J; Miao Y; Zhang J; Cao X
Cardiovasc Drugs Ther; 2020 Feb; 34(1):15-23. PubMed ID: 32062793
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet therapy in patients with diabetes mellitus.
Grove EL; Gregersen S
Curr Vasc Pharmacol; 2012 Jul; 10(4):494-505. PubMed ID: 22272895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
